KZA 0.00% $1.38 kazia therapeutics limited

nrt awarded us patent, page-2

  1. 4,756 Posts.
    Awarded US Patent for Isoflavins to Treat Menopause & PMS

    NOVOGEN LIMITED 2003-05-20 ASX-SIGNAL-G

    HOMEX - Sydney

    +++++++++++++++++++++++++
    Pharmaceutical company Novogen Limited has been granted a patent in
    the US over the use of its isoflavone technology in the treatment of
    the symptoms of menopause and pre-menstrual syndrome (PMS).

    The patent applies to the isoflavones genistein, daidzein,
    formononetin and biochanin, all of which are used commonly in
    pharmaceutical preparations and health supplements such as tablets,
    capsules, drinks and foodstuffs for the alleviation of the adverse
    symptoms of menopause and PMS.

    Novogen pioneered the research, development, manufacture and
    marketing of isoflavone technology through three of its own
    proprietary dietary supplements, Promensil(TM) for the treatment of
    the symptoms of menopause, Rimostil(TM), for the maintenance of bone
    and cholesterol health in post-menopausal women and Trinovin(TM) for
    the maintenance of prostate and urinary health for men.

    Novogen also has licensed part of its technology to the DuPont
    controlled company Solae for which it is receiving royalty payments.

    Novogen's managing director, Mr Christopher Naughton, said isoflavone
    supplements were widely used by women worldwide seeking a safe
    alternative to hormone replacement therapy for the maintenance of
    health and well being during and after menopause.

    "The granting of the patent adds value to product marketing and also
    strengthens potential for possible further licensing transactions,"
    Mr Naughton said.

    "While Novogen's principal corporate focus is on clinical trailing of
    various components of its phenolic hormone technology, it is a major
    competitive advantage to have a suite of patents around the
    isoflavone platform," Mr Naughton added.

    Novogen's isoflavone products are marketed globally and the company
    coordinates and manages its research and development programs
    utilising the expertise and clinical research capabilities of
    universities and hospitals in Australia and key international
    locations.

    More information on the Company can be found at www.novogen.com.

    ISSUED FOR : NOVOGEN LIMITED
    LISTINGS : ASX (CODE NRT), NASDAQ (CODE NVGN).
    FOR FURTHER MR CHRISTOPHER NAUGHTON, MANAGING DIRECTOR
    INFORMATION : NOVOGEN LIMITED, TEL (02) 9878 0088

    ISSUED BY : WESTBROOK COMMUNICATIONS
    CONTACT: DAVID REID TEL (02) 9231 0922 OR 0417 217 157

 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Last
$1.38
Change
0.000(0.00%)
Mkt cap ! $178.8M
Open High Low Value Volume
$1.35 $1.42 $1.35 $504.6K 368.5K

Buyers (Bids)

No. Vol. Price($)
1 2750 $1.38
 

Sellers (Offers)

Price($) Vol. No.
$1.39 2500 1
View Market Depth
Last trade - 16.10pm 11/05/2021 (20 minute delay) ?
(live)
Last
$1.38
  Change
0.000 ( 0.00 %)
Open High Low Volume
$1.41 $1.41 $1.34 4773
Last updated 15.53pm 11/05/2021 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.